Onco-Summaries: Daily Oncology Updates at a Glance

17/03/2026

---

• CRISM Therapeutics' irinotecan received the FDA ODD for malignant glioma

• Voro Therapeutics and Daiichi Sankyo sign a research collaboration for Next-Generation Tumor-Activated ADCs

---

CRISM Therapeutics' irinotecan received the FDA ODD for malignant glioma (Ref)

The US FDA granted the Orphan Drug Designation to CRISM Therapeutics Corporation's irinotecan for the treatment of malignant glioma.

• Chris McConville, Chief Scientific Officer, CRISM Therapeutics: "Receiving Orphan Drug Designation from the FDA is a strong validation of the potential of irinotecan-ChemoSeed. From a strategic perspective, this designation enhances the regulatory profile and potential commercial attractiveness of the programme and supports our strategy of advancing differentiated oncology assets that address significant unmet medical needs.

  
  

  • When combined with our Innovation Passport and participation in the UK's ILAP programme, we believe irinotecan-ChemoSeed is well positioned for constructive regulatory engagement as we progress with our registration-grade Phase 2 clinical trial of Irinotecan ChemoSeed in surgically resectable glioblastoma.''  

Return to Top

Voro Therapeutics and Daiichi Sankyo sign a research collaboration for Next-Generation Tumor-Activated ADCs (Ref)

Voro Therapeutics signed a research collaboration with Daiichi Sankyo through its Daiichi Sankyo Research Institute San Diego.

• Under the agreement, Voro Therapeutics will apply its PrimeBody masking and linker technologies to design and characterize masked ADC candidates directed against a selected oncology target

• The collaboration will leverage Voro's previous experience and demonstrated success in creating tumor-activated biologics, including its lead CD47 blocker program, which has shown improved therapeutic index in preclinical studies.

Return to Top